

# BIOTECH & PHARMA IN FRANCE

## KEY FACTS & FIGURES

- **The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany**
- **First producer of medicines in Europe with 220 production sites and 326 firms**
- **In 2008, overall consumption of pharmaceuticals in France increased by 7.1% (in quantity) and by 1.5 % (in value) to reach €33.4bn**
- **66% of French biotech resources are in the Paris and Lyon regions**
- **More than 100,000 people employed in the pharmaceutical sector including 22,500 in R&D**
- **Main key players invested an average of 15% of their turnover in R&D activities in 2008**



## Strengths

- One of the largest pharmaceutical markets in the world with more than 400 laboratories.
- Sanofi-Aventis, no 4 in the world, is headquartered in France with other major multinationals
- World-class clusters in Paris (Medicen) and Lyon (Lyonbiopôle)
- World-class public and private scientific research expertise
- France's regulatory environment, based on EU directives is considered as one of the most transparent in the world

## We can help you

**Many UK companies have contacted us to know more about the type of advice and support that we can provide. To find out more about market research activity tailored to your individual requirements, contact our UKTI team in Lyon.**

## CONTACT DETAILS

Laurent Faye  
Senior Trade Officer for Biotechnology & Pharmaceuticals in France  
Tel: +33 (0)4 72 77 83 21  
Email: laurent.faye@fco.gov.uk

[www.ukti.gov.uk](http://www.ukti.gov.uk)  
[www.ukinfrance.fco.gov.uk](http://www.ukinfrance.fco.gov.uk)

## Opportunities to work with French partners

- 6 biopharma sub-sectors are sources of many challenges and collaborative opportunities for British R&D organisations:
  - o Industrialisation of stem cells
  - o Bio manufacturing
  - o Biomarkers and personalised medicine
  - o Biofuels
  - o And, with the growing convergence between biopharma and medtech sectors, complex bioprosthesis, together with
  - o Micro and nano-technologies
- Ageing population stimulating demand for chronic treatment (by 2030, 28% of the French population should be over 65).
- The potential for generics market growth is considerable (market share 20% in volume).
- Government support to life science industry through the creation of the ISF -Investment Strategic Fund- (allocated amount = €1,55bn).